88 related articles for article (PubMed ID: 1504664)
1. The tumor-cytokine transplantation assay and the antitumor activity of interleukin-4.
Tepper RI
Bone Marrow Transplant; 1992; 9 Suppl 1():177-81. PubMed ID: 1504664
[No Abstract] [Full Text] [Related]
2. Molecular engineering of the antitumor immune response.
Pardoll DM; Golumbek P; Levitsky H; Jaffee L
Bone Marrow Transplant; 1992; 9 Suppl 1():182-6. PubMed ID: 1387016
[No Abstract] [Full Text] [Related]
3. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
5. Experimental design for the evaluation of the antitumor action of cytokines.
Ciolli V; Sestili P; Brigato M; Gabriele L; Varano F; Locardi C; Belardelli F
Ann Ist Super Sanita; 1990; 26(3-4):441-51. PubMed ID: 2091505
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
8. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.
Kim JH; Gong SJ; Yoo NC; Lee H; Shin DH; Uhm HD; Jeong SJ; Cho JY; Rha SY; Kim YS; Chung HC; Roh JK; Min JS; Kim BS
Oncol Rep; 1999; 6(1):49-54. PubMed ID: 9864400
[TBL] [Abstract][Full Text] [Related]
9. Towards endothelial-cell-directed cancer immunotherapy: in vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells.
Ojeifo JO; Su N; Ryan US; Verma UN; Mazumder A; Zwiebel JA
Cytokines Mol Ther; 1996 Jun; 2(2):89-101. PubMed ID: 9384693
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
12. Cytokines and cancer: experimental systems.
Blankenstein T; Rowley DA; Schreiber H
Curr Opin Immunol; 1991 Oct; 3(5):694-8. PubMed ID: 1755987
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer.
Wei MX; Tamiya T; Hurford RK; Boviatsis EJ; Tepper RI; Chiocca EA
Hum Gene Ther; 1995 Apr; 6(4):437-43. PubMed ID: 7612701
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
18. In vivo analysis of the 'bystander effect': a cytokine cascade.
Ramesh R; Marrogi AJ; Munshi A; Abboud CN; Freeman SM
Exp Hematol; 1996 Jun; 24(7):829-38. PubMed ID: 8647234
[TBL] [Abstract][Full Text] [Related]
19. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines.
Finnegan A; Mikecz K; Tao P; Glant TT
J Immunol; 1999 Nov; 163(10):5383-90. PubMed ID: 10553063
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells.
Shan BE; Hao JS; Li QX; Tagawa M
Cell Mol Immunol; 2006 Feb; 3(1):47-52. PubMed ID: 16549049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
